| scholarly article | Q13442814 |
| P50 | author | Charles Swanton | Q30419560 |
| Jean-Charles Soria | Q33120580 | ||
| P2093 | author name string | J-C Soria | |
| L L Siu | |||
| F Andre | |||
| E Mardis | |||
| M Salm | |||
| P2860 | cites work | EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 |
| The genetic basis for cancer treatment decisions | Q26849200 | ||
| From patients to partners: participant-centric initiatives in biomedical research | Q27016065 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma | Q37626102 | ||
| Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives | Q38082503 | ||
| National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network | Q38214265 | ||
| Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens | Q39210091 | ||
| Tracking the clonal origin of lethal prostate cancer | Q41762568 | ||
| Systematic investigation of cancer-associated somatic point mutations in SNP databases | Q46304716 | ||
| From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets | Q47445570 | ||
| Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). | Q50724452 | ||
| Chipping away at the lung cancer genome | Q54525027 | ||
| High-throughput oncogene mutation profiling in human cancer | Q57693480 | ||
| Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study | Q27851528 | ||
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
| Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer | Q27852282 | ||
| Ceritinib in ALK-rearranged non-small-cell lung cancer | Q27852989 | ||
| Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine | Q27853005 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| Discovery and saturation analysis of cancer genes across 21 tumour types | Q28305204 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| The causes and consequences of genetic heterogeneity in cancer evolution | Q29615848 | ||
| ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing | Q29616235 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| The translation of cancer genomics: time for a revolution in clinical cancer care | Q33772611 | ||
| Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial | Q34033475 | ||
| Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma | Q34069375 | ||
| Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. | Q34116750 | ||
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs | Q34175045 | ||
| Cancer heterogeneity: implications for targeted therapeutics | Q34321565 | ||
| Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma | Q34391844 | ||
| Designing Transformative Clinical Trials in the Cancer Genome Era | Q34669926 | ||
| A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer | Q34760642 | ||
| Evaluating many treatments and biomarkers in oncology: a new design | Q35379179 | ||
| Radiation-induced DNA damage and delayed induced genomic instability | Q35559115 | ||
| All-trans retinoic acid (ATRA) therapeutical effect in acute promyelocytic leukemia | Q35607394 | ||
| Clonal architecture of secondary acute myeloid leukemia | Q35872658 | ||
| Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing | Q36256943 | ||
| Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation | Q36800445 | ||
| Oncogene addiction | Q37152445 | ||
| Assuring the quality of next-generation sequencing in clinical laboratory practice | Q37306277 | ||
| Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profiling | Q37395388 | ||
| P433 | issue | 12 | |
| P921 | main subject | prioritization | Q11888847 |
| P304 | page(s) | 2295-2303 | |
| P577 | publication date | 2014-10-24 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Prioritizing targets for precision cancer medicine | |
| P478 | volume | 25 |
| Q89967608 | A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants |
| Q96127147 | A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study |
| Q36294743 | A decision support framework for genomically informed investigational cancer therapy |
| Q61866333 | A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) |
| Q48292830 | Adapting the drivers to the road: a new strategy for cancer evolution? |
| Q26800999 | Big Data Analytics in Healthcare |
| Q91851261 | Circulating Tumor Cells and Fibronectin 1 in the Prognosis of Nasopharyngeal Carcinoma |
| Q64237922 | Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer |
| Q33873653 | Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. |
| Q39796583 | Consensus on precision medicine for metastatic cancers: a report from the MAP conference. |
| Q53117937 | Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials |
| Q36317783 | Data resources for the identification and interpretation of actionable mutations by clinicians. |
| Q38816901 | Defining actionable mutations for oncology therapeutic development. |
| Q38839110 | Drug discovery in advanced prostate cancer: translating biology into therapy |
| Q47552057 | Effects of rat bone marrow-derived mesenchymal stem cells on breast cancer cells with differing hormone receptor status |
| Q35794451 | Enhancing cancer clonality analysis with integrative genomics. |
| Q47893147 | Evidence-Based Precision Oncology with the Cancer Targetome. |
| Q34529131 | Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. |
| Q39288360 | Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. |
| Q58802587 | Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance |
| Q28648163 | Extracting research-quality phenotypes from electronic health records to support precision medicine |
| Q28597289 | Facilitating a culture of responsible and effective sharing of cancer genome data |
| Q53461042 | Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. |
| Q48013156 | Functional precision cancer medicine-moving beyond pure genomics |
| Q38597700 | Glioblastoma targeted therapy: updated approaches from recent biological insights |
| Q35879104 | HitWalker2: visual analytics for precision medicine and beyond |
| Q38389841 | Improving Clinical Trial Efficiency: Thinking outside the Box. |
| Q49542418 | In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening |
| Q50099775 | Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform |
| Q38966415 | Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. |
| Q36851421 | Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers |
| Q87745740 | Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer |
| Q89288772 | Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis |
| Q92000742 | NCAPG Is a Promising Therapeutic Target Across Different Tumor Types |
| Q38885953 | Noninvasive strategies for breast cancer early detection. |
| Q90254699 | Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology |
| Q50115884 | PRECISION ONCOLOGY DECISION SUPPORT: CURRENT APPROACHES AND STRATEGIES FOR THE FUTURE. |
| Q55017642 | PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. |
| Q47199187 | Personalized cancer therapy: leveraging a knowledge base for clinical decision-making |
| Q36853558 | Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays |
| Q53939793 | Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways |
| Q38981782 | Progress and prospects for the discovery of biomarkers for gastric cancer: a focus on proteomics |
| Q64990242 | Prospective analysis of 895 patients on a UK Genomics Review Board. |
| Q92381830 | The Somatic Curation and Interpretation Across Laboratories (SOCIAL) project-current state of solid-tumour variant interpretation for molecular pathology in Canada |
| Q59336100 | Variant information systems for precision oncology |
Search more.